Genelabs deal boosts GSK’s anti-virus research
GlaxoSmithKline has acquired Genelabs Technologies, a biopharmaceutical company focused on the discovery and development of compounds for infectious diseases, for some $57 million (£35 million) in a $1.30 per share cash offer.
News